Shares of Synairgen plc (LON: SNG) today fell 12.3% after the company announced that it had raised £80 million via a share placement priced at 175p per share, a 22.5% discount to yesterday’s closing price of 226p.
Synairgen also has the option of raising another £7 million from investors who did not participate in the latest capital raise.
The biotech company said that it will use the money to fund the final clinical-stage trials for its SNG001 COVID-19 drug as well as the mass production of the same drug starting next year.
Ready to put what you’ve learned into practice?
Try IG’s platform with £10,000 in virtual funds and practise trading
without putting your own money at risk.
Try IG with a demo account →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Learn the markets with IG Academy
Build your knowledge with IG Academy educational content, then use a
demo account to practise what you’ve learned on the IG platform.
Explore IG →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
See how trading works before risking real money
IG’s demo gives you access to thousands of markets and £10,000 in
virtual funds, so you can explore the platform and test your ideas first.
Open an IG demo →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Turn trading theory into practical experience
Learn with IG Academy, explore charts and market tools, and practise
strategies in a simulated trading environment before going live.
Start practising with IG →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Ready to take your learning further?
IG combines market education, analysis and an established trading platform,
giving you the tools to keep learning as you develop your trading skills.
Discover IG →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
The company said that phase III clinical trials of the drug will begin during this quarter and will involve 900 patients in 20 countries following the positive results of the phase II trials, which registered a 79% success rate in patients with severe symptoms of COVID-19.
Richard Marsden, Synairgen’s CEO said: “Having demonstrated the great promise of SNG001 in hospitalised COVID-19 patients earlier this year, we are delighted to have now received the financial support to be able to progress this potential breakthrough treatment in such a critical area of unmet need.”
Synairgen share price
Synairgen shares today fell 12.3% to trade at 198p having dropped from Wednesday’s closing price of 226p.
People who read this also read:
